Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week, Multi-center, Randomized, Open-Label Clinical Trial to Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME Study)

NCT05238012 is registered in ClinicalTrials.gov with Heart Health Research Center as lead sponsor.

NCT NCT05238012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05238012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week, Multi-center, Randomized, Open-Label Clinical Trial to Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME Study)
Lead sponsor
Heart Health Research Center
Phase
Phase 4
Overall status
Completed
Start date
August 2, 2022
Completion date
April 2, 2024
Enrollment
392 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolism disorder, glucose, metabolism disorder, lipid